EGFR and neoplasm: Furthermore, REGN5093-M114 demonstrated potency in reducing tumor growth in EGFR-mutant NSCLC cases with specific genetic alterations, such as PTEN loss or MET Y1230C mutation, especially after previous treatment with osimertinib and savolitinib.